Novo Nordisk’s diabetes and obesity portfolio faces evolving competition and legal developments, while pharmaceutical research and the NYSE Composite provide broader market context.

Novo Nordisk stock is steady after JPMorgan raised its price target to DKK 275 and lifted 2026 sales

Novo Nordisk stock is holding its ground after the company reported higher adjusted Q2 2026 profits,

Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.

On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and not yet approved by regulators anywhere. Why This Matters Lilly is trying to shut down a […]

On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly and Company (NYSE:LLY) are locked in a zero-sum battle for the same shrinking pool of […]

On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly and Company (NYSE:LLY) are locked in a zero-sum battle for the same shrinking pool of […]

Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The advancement of LX9851 adds a new mechanism of action to Novo Nordisk